Rosuvastatin

Rosuvastatin belongs to the statins, formally the HMG-CoA reductase inhibitors, a family of drugs that lower blood cholesterol. It is one of the more potent members of the class, producing large reductions in low-density lipoprotein cholesterol at commonly used doses ^[1]. Chemically it is distinctive among statins for containing a sulfonyl group bearing sulfur, and the marketed product is the calcium salt, rosuvastatin calcium ^[2].

The drug was developed by the company that became AstraZeneca, patented in the early 1990s, and approved in the United States in 2003. It is a prescription-only medicine sold under the brand name Crestor and, since its patents lapsed, as a widely available generic; it ranks among the most frequently prescribed medications in the United States ^[1]. It is supplied as oral tablets in a range of strengths.

Rosuvastatin is used both to treat dyslipidemia, meaning abnormal blood lipids, and to prevent cardiovascular disease in people at increased risk, alongside lifestyle measures such as diet, exercise, and weight control. Comparative trials showed it to be more effective than several other statins at lowering LDL cholesterol at equivalent doses ^[2]. Imaging studies such as the ASTEROID trial demonstrated that intensive treatment could actually shrink the fatty plaques lining coronary arteries ^[4], and the large JUPITER trial found that it reduced heart attacks, strokes, and cardiovascular deaths even in apparently healthy people who had normal cholesterol but raised C-reactive protein ^[3].

Rosuvastatin is taken by mouth, usually once a day, and can be used with or without food. Like other statins it is generally well tolerated, though it carries the class's recognized risks of muscle symptoms and a small increase in the chance of developing diabetes, and it is used cautiously alongside certain interacting drugs ^[3].

Rosuvastatin is a widely used, extensively studied statin whose main risk is muscle toxicity, ranging from myalgia to rare rhabdomyolysis, and it can also raise liver enzymes and slightly increase the risk of new-onset diabetes. The chance of muscle injury rises with higher doses, certain drug interactions, hypothyroidism, and in East Asian populations, who may have higher drug exposure. It should not be used during pregnancy or breastfeeding.

Rosuvastatin is a substrate of the organic anion transporting polypeptide OATP1B1 and the breast cancer resistance protein BCRP. Cyclosporine, a potent OATP1B1 inhibitor, significantly increases rosuvastatin plasma concentrations through reduced hepatic uptake; this is a pharmacokinetic interaction where cyclosporine reduces rosuvastatin clearance, raising the risk of muscle toxicity ^[23].

BCRP inhibitors including febuxostat and ticagrelor have been shown in pharmacovigilance analysis to increase the risk of rosuvastatin-induced rhabdomyolysis, with reporting odds ratios of 2.47 and 4.15 respectively ^[24]. What remains unclear from the literature is the magnitude of interaction with partial OATP1B1 or BCRP inhibitors, and whether genetic polymorphisms in these transporters meaningfully alter interaction risk in individual patients. The interaction of rosuvastatin with the numerous other lipophilic drugs that might compete for OATP1B1 transport has not been systematically evaluated.

Checking a whole stack? Run it through interactions + stacks.

Rosuvastatin was first synthesized by chemists at the Japanese company Shionogi in the early 1990s, where it carried the code S-4522 and was recognized as an unusually potent inhibitor of HMG-CoA reductase. Shionogi licensed the compound to AstraZeneca, which advanced it through clinical development under the designation ZD4522 and brought it to market. The United States Food and Drug Administration approved it in 2003 under the brand name Crestor for the treatment of elevated cholesterol.

It stood out among the statins for its high potency and relatively hydrophilic character, allowing strong reductions in LDL cholesterol at comparatively low doses. Its reputation was further shaped by the landmark JUPITER trial, published in 2008, which showed that it prevented cardiovascular events in people with normal LDL but elevated C-reactive protein, evidence of anti-inflammatory effects beyond lipid lowering. It is now available generically and remains one of the most widely prescribed statins.

Rosuvastatin is often described as the most potent statin available, capable of achieving large reductions in LDL cholesterol that help many patients reach ambitious treatment targets. Its strong evidence base, anchored by the JUPITER trial, extends its appeal beyond simple cholesterol lowering, since that study demonstrated fewer heart attacks and strokes even in people selected for inflammation rather than high LDL.

Physicians value its efficacy at modest doses and its hydrophilic profile, which some argue contributes to a favorable tolerability. Like all statins it can occasionally cause muscle symptoms and warrants attention to liver and, at high doses, kidney parameters, and it is not a substitute for the lifestyle measures that underpin cardiovascular health. For the prevention of heart attack, stroke, and related events, however, it is regarded as one of the most powerful and well-studied options in modern medicine.